title: Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
authors: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors: Allen
authors: A
authors: Jeremias
authors: Deepak L
authors: DL
authors: Bhatt
authors: Derek P
authors: DP
authors: Chew
authors: Khaled M
authors: KM
authors: Ziada
authors: Abdulhay
authors: A
authors: Albirini
authors: Sorin J
authors: SJ
authors: Brener
authors: A Michael
authors: AM
authors: Lincoff
authors: Eric J
authors: EJ
authors: Topol
authors: Stephen G
authors: SG
authors: Ellis
mesh_terms: D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality / Q000601:surgery*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009820:Ohio / Q000453:epidemiology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use; D019106:Postoperative Hemorrhage / Q000209:etiology; D012307:Risk Factors; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D006454:Hemoglobins; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab